An Epidemiological Study Of Pulmonary Hypertension In Turkish Adult Population

Yıl 2015, Cilt: 6 Sayı: 24, 24 - 31, 30.12.2015

Mehmet Pektas Ayhan Pektas Sadik Emren Mustafa Aldemir Gulay Ozkececi Serdar Kula Ismet Dogan

https://doi.org/10.17944/mkutfd.86233

Cited By: 1

Öz

Objective: The present study aims to evaluate the nationwide epidemiological characteristics of adulthood pulmonary hypertension (PH) within whole Turkish population over a period of five years using the registry of the National Health Insurance System.

Methods: All individuals aged more than 18 years who were admitted to a Turkish hospital for the first time between 2009 and 2013 with a discharge diagnosis of primary PH (ICD-10 code I27.0) and secondary PH (ICD-10 code I27.2) were identified.

Results: The overall annual prevalence of primary PH during adulthood was 9.6 cases per million. When compared with other age groups, the number of individuals aged more than 45 years was significantly higher in adults affected by primary PH during the study period (p=0.001 for all years). The female to male ratio was 2.2:1 for adulthood primary PH throughout the study period. The number of patients settled in the Northwestern Anatolia was significantly higher in the primary PH group (p<0.05 for all years). The overall annual prevalence of secondary PH in adults was 6.0 cases per million. When compared with other age groups, the number of individuals aged more than 45 years was significantly higher in adults affected by secondary PH during the study period (p=0.001 for all years).

Conclusion: The prevalence of adulthood PH in Turkey may be higher than that of adulthood PH in Western countries and adulthood PH usually affects Turkish individuals aged over 45 years.

Keywords: Adult; epidemiology; pulmonary hypertension

Anahtar Kelimeler

-

Erişkin Türk Toplumunda Pulmoner Hipertansiyon; Epidemiyolojik Çalışma

Öz

Amaç: Bu çalışma beş yıllık periyodu kapsayacak şekilde, Türk popülasyonunda erişkin pulmoner hipertansiyonunun epidemiyolojik amaçlamaktadır. Ülkesel boyutta ulusal sağlık sigorta sistemi kayıtları baz alınmıştır. karakteristiklerinin incelenmesini

Anahtar Kelimeler

Erişkin, epidemiyoloji, pulmoner hipertansiyon

Kaynakça

• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:34-41.
• Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension. Hum Genet 2014;133:471-9.
• Seferian A, Simonneau G. Pulmonary hypertension: definition, diagnostic and new classification. Presse Med 2014;43:935-44.
• Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-9.
• Savale L, Sattler C, Sitbon O. Pulmonary hypertension in liver diseases. Presse Med 2014;43:970-80.
• Araújo I, Enjuanes-Grau C, Lopez-Guarch CJ, et al. Pulmonary arterial hypertension related to human immunodeficiency virus infection: A case series. World J Cardiol 2014;6:495-501.
• Seferian A, Chaumais MC, Savale L, et al. Drugs induced pulmonary arterial hypertension. Presse Med 2013;42:303-10.
• Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425–36.
• Barst RJ, Mc GoonM, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:40–47.
• McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62:51-9.
• Lador F, Herve P. A practical approach of pulmonary hypertension in the elderly. Semin Respir Crit Care Med 2013; 34: 654-64.
• Sahin AA. The key to health services in Turkey: new perspectives on leadership and hospital management. World Hosp Health Serv 2014; 50: 7-8.
• World Health Organization. Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death. 10th revision. Geneva, World Health Organization, 1996.
• Atun R, Aydın S, Aran M, Gürol I, Chakraborty S, Akdag R. Health-care reform in Turkey: far from perfect - Authors' reply. Lancet 2014; 383(9911): e1.
• Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987; 107: 216–23.
• Abenhaim L, Moride Y, Brenot F, et al. Appetite suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609–16.
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023–30.
• McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78–92.
• Galie N, Seeger W, Naeije R, Simmoneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:76–88.